BALCAO · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Aptose Biosciences Inc. APTOF
9 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-10.41
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 9-year series below
Revenue
Net income
Per share
USD -10.41
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-252.9%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 10.0M
total assets, end of FY2025
Total assetsUSD 10.0M
EquityUSD -27.2M
CashUSD 935,000.00
Current ratio0.69×
Equity funds -271% of total assets.
History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
Operating income $B
·
·
·
·
·
·
·
·
·
EBITDA $B
·
·
·
·
·
·
·
·
·
Income tax $B
0.0
0.0
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.1
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
−10.41
−36.38
−227.43
−6.80
−0.73
−0.67
−0.52
−0.86
−0.52
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
·
·
−294.0
−74.7
−67.7
−51.9
−48.7
−237.8
−114.1
Shares out B
0.00
0.00
0.00
0.01
0.09
0.09
0.08
0.04
0.03
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
27 of 27
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed